Generally, the grades of dactylitis and enthesitis in PsA patients have been suggested to be partly influenced, that is, enhanced, by TNF-α, which is supported by the efficacy of TNF-α blockers in PsA therapy [23-26]. This evidence concerns the gene TNF and enthesitis.